Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VERU
VERU logo

VERU Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Veru Inc (VERU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.240
1 Day change
-1.75%
52 Week Range
7.400
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Veru Inc (VERU) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are neutral, options sentiment is weak, and the company's financial performance is declining. There are no significant positive catalysts or trading signals to support a buy decision.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 36.099, and moving averages are converging, indicating no clear trend. Key support is at 2.313, and resistance is at 2.465. The stock has a 50% chance of declining in the short term (-2.11% next day, -1.81% next week, -5% next month).

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate minimal bearish sentiment, but the overall options activity is low, with implied volatility at 182.72% and an IV rank of 17.26, suggesting limited interest in the stock.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
2

Positive Catalysts

  • NULL identified. There is no recent news, no significant insider or hedge fund activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The company's financial performance is deteriorating, with a YoY net income drop of -40.39% and EPS down -57.38%. Additionally, there are no strong technical or options signals, and the stock has a higher probability of short-term decline.

Financial Performance

In Q1 2026, Veru Inc reported a 0% YoY revenue growth, a net income drop of -40.39%, and an EPS decline of -57.38%. Gross margin remained at 0%. The financials indicate a struggling company with no growth momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast VERU stock price to rise
1 Analyst Rating
Wall Street analysts forecast VERU stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.280
sliders
Low
25
Averages
25
High
25
Current: 2.280
sliders
Low
25
Averages
25
High
25
Canaccord
NULL -> Buy
initiated
$25
AI Analysis
2025-12-18
Reason
Canaccord
Price Target
$25
AI Analysis
2025-12-18
initiated
NULL -> Buy
Reason
Canaccord initiated coverage of Veru with a Buy rating and $25 price target. Veru is positioned as a differentiated biotech in obesity drug development, with lead candidate enobosarm, an oral selective androgen receptor agonist, being evaluated in Phase IIb alongside a GLP-1 receptor agonist to preserve muscle during weight loss, the analyst tells investors in a research note. A second Phase IIb trial is planned for 1Q26, with top-line data expected in 1H28, the firm says.

People Also Watch